Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
Drug Topics Hospital Pharmacists' Report

Drug Topics
Hospital
Pharmacists' Report

DrugTopics.com

April 5, 2012

CLINICAL NEWS

Rivaroxaban as effective as standard therapy for treating PE with lower risk of bleeding

Rivaroxaban, an oral blood thinner, is equally effective as standard therapy for the treatment of pulmonary embolism and may cause fewer bleeding complications, according to new data. » More

Risk of secondary cases of C. difficile in households doesn’t justify interventions

The risk of Clostridium difficile infection among households is too low to justify interventions, other than avoiding unnecessary antimicrobials, according to a new study published in April’s Journal of Infection. » More

CONTINUING EDUCATION

The latest FDA drug approvals: What you need to know

Of the 35 new molecular entities approved by FDA in 2011, 17 are considered groundbreaking because of their potential to make a real difference in the lives of patients.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

CLINICAL NEWS

New guidelines: Don’t treat most sinus infections with antibiotics

The majority (90% to 98%) of sinus infections are caused by viruses and should not be treated with antibiotics, according to new guidelines from the Infectious Diseases Society of America. » More

Rituximab may be better second-line RA therapy when anti-TNF fails

Switching patients with rheumatoid arthritis to rituximab (Rituxan, Genentech) may be more effective than switching them to a second alternative anti-tumor necrosis factor (anti-TNF) after a first anti-TNF therapy has failed, according to a study published online in Arthritis Care & Research. » More

Blood-pressure drug might curb PTSD-related nightmares

The blood-pressure medication prazosin was found to be an effective treatment to curb nightmares related to post-traumatic stress disorder, according to a poster presentation at the 20th European Congress of Psychiatry in Prague. » More
Twitter  

Follow us on Twitter
Twitter  

Like us on Facebook

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Voices

•

Anticoagulation Update

•

JP at Large

•

View from the Zoo

•

Viewpoints

•

Regulatory & Legal

 

Meetings & Events

Digital Edition

•

View current edition
Cover
 

Editorial Questions? Click Here.
Sales, Reprints, Classifieds: Click Here.

 Powered by Modern Medicine Advanstar Medical Communications Group

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.